Abo Bibliothek: Guest
Critical Reviews™ in Eukaryotic Gene Expression

Erscheint 6 Ausgaben pro Jahr

ISSN Druckformat: 1045-4403

ISSN Online: 2162-6502

The Impact Factor measures the average number of citations received in a particular year by papers published in the journal during the two preceding years. 2017 Journal Citation Reports (Clarivate Analytics, 2018) IF: 1.6 To calculate the five year Impact Factor, citations are counted in 2017 to the previous five years and divided by the source items published in the previous five years. 2017 Journal Citation Reports (Clarivate Analytics, 2018) 5-Year IF: 2.2 The Immediacy Index is the average number of times an article is cited in the year it is published. The journal Immediacy Index indicates how quickly articles in a journal are cited. Immediacy Index: 0.3 The Eigenfactor score, developed by Jevin West and Carl Bergstrom at the University of Washington, is a rating of the total importance of a scientific journal. Journals are rated according to the number of incoming citations, with citations from highly ranked journals weighted to make a larger contribution to the eigenfactor than those from poorly ranked journals. Eigenfactor: 0.00058 The Journal Citation Indicator (JCI) is a single measurement of the field-normalized citation impact of journals in the Web of Science Core Collection across disciplines. The key words here are that the metric is normalized and cross-disciplinary. JCI: 0.33 SJR: 0.345 SNIP: 0.46 CiteScore™:: 2.5 H-Index: 67

Indexed in

New Prospectives of Prostate Cancer Gene Therapy: Molecular Targets and Animal Models

Volumen 11, Ausgabe 1-3, 2001, 44 pages
DOI: 10.1615/CritRevEukarGeneExpr.v11.i1-3.50
Get accessGet access

ABSTRAKT

Prostate cancer is the most common cancer and the second leading cause of cancer-related death among North American men. The low cure rate for prostate cancer is associated with the fact that many patients have metastatic disease at the time of disease presentation. Currently available therapeutic modalities for prostate cancer, such as surgery, radiation, hormone therapy, and chemotherapy, have failed to cure patients because these therapies are not sufficiently tumor-specific, resulting in dose-limiting toxicity. Therefore, gene therapy may offer great promise in this regard. In this article, we summarize current advances in gene therapy technologies for the treatment of cancer in general, and future prospects for treatment of human prostate cancer metastasis. We specifically emphasize current studies for improvement, both in the efficiency and the specificity of viral and nonviral vectors, and restricted transgene expression in tumors, to achieve selective targeting with minimized host organ toxicity, based on the molecular understanding of potential regulatory differences between normal and tumor cells. Cell and animal models used to study prostate cancer growth, invasion, and metastasis, and their usefulness in preclinical evaluation of therapeutic vectors in the treatment of protate cancer skeletal metastasis are also discussed.

REFERENZIERT VON
  1. Chung Leland W.K., Huang Wen-Chin, Sung Shian-Ying, Wu Daqing, Odero-Marah Valerie, Nomura Takeo, Shigemura Katsumi, Miyagi Tohru, Seo Seogil, Shi Chumeng, Molitierno Joe, Elmore James, Anderson Cynthia, Isotani Shuji, Edlund Magnus, Hsieh Chia-Ling, Wang Ruoxiang, Shehata Bahig, Zhau Haiyen E., Stromal-Epithelial Interaction in Prostate Cancer Progression, Clinical Genitourinary Cancer, 5, 2, 2006. Crossref

  2. Sung Shian-Ying, Chung Leland W.K., Prostate tumor-stroma interaction: molecular mechanisms and opportunities for therapeutic targeting, Differentiation, 70, 9-10, 2002. Crossref

  3. Wang Ruoxiang, He Hui, Sun Xiaojuan, Xu Jianchun, Marshall Fray F., Zhau Haiyen, Chung Leland W.K., Fu Haian, He Dalin, Transcription variants of the prostate-specific PrLZ gene and their interaction with 14-3-3 proteins, Biochemical and Biophysical Research Communications, 389, 3, 2009. Crossref

  4. Sung Shian-Ying, Hsieh Chia-Ling, Wu Daqing, Chung Leland W.K., Johnstone Peter A.S., Tumor Microenvironment Promotes Cancer Progression, Metastasis, and Therapeutic Resistance, Current Problems in Cancer, 31, 2, 2007. Crossref

  5. Sanlioglu Ahter Dilsad, Koksal Ismail Turker, Ciftcioglu Akif, Baykara Mehmet, Luleci Guven, Sanlioglu Salih, Differential Expression of TRAIL and its Receptors in Benign and Malignant Prostate Tissues, Journal of Urology, 177, 1, 2007. Crossref

  6. Aneja Ritu, Miyagi Tohru, Karna Prasanthi, Ezell Tucker, Shukla Deep, Vij Gupta Meenakshi, Yates Clayton, Chinni Sreenivasa R., Zhau Haiyen, Chung Leland W.K., Joshi Harish C., A novel microtubule-modulating agent induces mitochondrially driven caspase-dependent apoptosis via mitotic checkpoint activation in human prostate cancer cells, European Journal of Cancer, 46, 9, 2010. Crossref

  7. Caceres Gisela, Zankina Ralitza, Zhu XiaoYun, Jiao Jin-an, Wong Hing, Aller Alex, Andreotti Peter, Determination of chemotherapeutic activity in vivo by luminescent imaging of luciferase-transfected human tumors, Anti-Cancer Drugs, 14, 7, 2003. Crossref

  8. de Dios Eugenio Santos, The use of animal models in cancer research, Revista de Oncología, 4, 2, 2002. Crossref

  9. Hsieh Chia-Ling, Gardner Thomas A, Miao Li, Balian Gary, Chung Leland W K, Cotargeting tumor and stroma in a novel chimeric tumor model involving the growth of both human prostate cancer and bone stromal cells, Cancer Gene Therapy, 11, 2, 2004. Crossref

Digitales Portal Digitale Bibliothek eBooks Zeitschriften Referenzen und Berichte Forschungssammlungen Preise und Aborichtlinien Begell House Kontakt Language English 中文 Русский Português German French Spain